CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5 enrolled
Drug / intervention
Azilsartan (TAK-536)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05107960
NCT05107960N/ACompleted

Special Drug Use Surveillance; AZILVA Tablets and AZILVA Granules 1% in Pediatric Use

Takeda·observational·Posted Nov 4, 2021·Updated Sep 10, 2025

In Brief

An observational study evaluating Azilsartan (TAK-536) for Hypertension. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The main aim of this study is to check for side effects from treatment with azilsartan and how well azilsartan controls blood pressure in children from 6 to less than 16 years old with high blood pressure. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. During the study, participants with high blood pressure will take azilsartan tablets or azilsartan granules once a day according to their clinic's standard practice. The study doctors will check for side effects from azilsartan for up to 12 months after treatment starts.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedNov 4, 2021
Enrollment StartDec 16, 2021
Primary CompletionAug 31, 2024
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4.7 years ago

Interventions

Azilsartan (TAK-536)drug

Azilsartan Tablets, Azilsartan Granules